| Name | Title | Contact Details |
|---|
4G Clinicals suite of innovative RTSM and clinical supply optimization software provides the right-sized support for any phase or trial complexity. At 4G Clinical, all studies are supported by a team of RTSM experts to advise trial teams on the best path forward. Our operations team distinguishes itself through their extensive industry expertise and deep understanding of trial designs and mid-study adjustments. 4G Clinical is committed to helping sponsors and CROs follow the science, wherever it may lead, as quickly and as safely as we can. While we will not discover the next novel compound in the lab, we are doing our part by leveraging our extensive experience and technological innovations to bring speed and agility to clinical trials. As a critical partner throughout clinical development, we can help you seamlessly transition and scale your trials through both protocol and supply complexities to help bring crucial medicines to those who need them, faster. To learn more about how we are tackling the bottlenecks in clinical trials through our innovative solutions, Prancer RTSM® and 4C Supply®, visit us at www.4gclinical.com.
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
Created by the 1975 merger of Sigma Chemical Company and Aldrich Chemical Company, Sigma-Aldrich since grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000 at the time of its acquisition by Merck.
CBCC has treated over 75,000 patients since we first opened. We have continually expanded and have earned the recognition as the largest free standing, privately held cancer center in the nation. While our motivation has always been to offer the finest care available, our story starts in a small office in 1984. Dr. Ravi Patel opened a 1200 square foot cancer clinic as a way to bring his vision of providing cancer patients with specialized medical and emotional care to Bakersfield. In the years since, CBCC has changed in many ways, but the purpose has always remained the same—we believe you shouldn`t have to travel the state for state-of-the-art cancer care.